Mustang Bio, Inc. - MBIO STOCK NEWS

Mustang Bio (NASDAQ: MBIO) announced that the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to its lentiviral gene therapy MB-107 for treating X-linked severe combined immunodeficiency (XSCID) in infants. This milestone comes as Mustang prepares for a pivotal Phase 2 clinical trial. The therapy has previously received ATMP and Orphan Drug designations from the EMA and FDA. XSCID, a rare genetic disorder, severely compromises the immune system and affects approximately 1 in 225,000 births.

Mustang Bio, Inc. (NASDAQ: MBIO) announced it received a $300,000 tax incentive from the Massachusetts Life Sciences Center (MLSC) to create 20 new jobs in 2021, maintaining this headcount through 2025. The MLSC awarded $19.5 million in total to various life science companies. Mustang's CEO, Manuel Litchman, expressed gratitude for the award, noting its significance amid stiff competition. This funding will aid the company's advancement in gene and CAR T cell therapies, which aim to address hematologic cancers and rare genetic diseases.

Mustang Bio, Inc. (NASDAQ: MBIO) announced that Dr. Manuel Litchman, President and CEO, will present at the Raymond James Human Health Innovation Conference from June 21-23, 2021. Mustang's presentation is scheduled for June 23, 2021, at 8:00 a.m. ET and will be available via webcast for 30 days. The company focuses on cell and gene therapies aimed at treating hematologic cancers, solid tumors, and rare genetic diseases, partnering with leading medical institutions to advance CAR T therapies and gene therapy for genetic disorders.

Mustang Bio (NASDAQ: MBIO) announced encouraging interim data from a Phase 1/2 clinical trial of MB-106, a CD20-targeted CAR T cell therapy for high-risk B-cell non-Hodgkin lymphomas (B-NHL) and chronic lymphocytic leukemia (CLL). The trial showed a 93% overall response rate and a 67% complete response rate among 15 patients. The therapy demonstrated a favorable safety profile, with only 40% of patients experiencing cytokine release syndrome. Mustang aims to initiate a multicenter Phase 1/2 trial later in the year after FDA acceptance of their IND application.

Mustang Bio (NASDAQ: MBIO) will host a webinar on June 15, 2021, at 1:00 p.m. ET to discuss the MB-106 CD20-targeted CAR T cell therapy for high-risk B-cell non-Hodgkin lymphomas and chronic lymphocytic leukemia. Dr. Mazyar Shadman from Fred Hutch will present interim results from the ongoing Phase 1/2 clinical trial. Mustang's management will also share details regarding the initiation of the trial after the FDA accepted its Investigational New Drug application. This presentation is scheduled ahead of the European Hematology Association 2021 Virtual Congress.

Mustang Bio has initiated a clinical trial at City of Hope for its MB-101 therapy targeting leptomeningeal brain tumors, including glioblastoma, ependymoma, and medulloblastoma. The trial involves 30 patients to assess safety and feasibility, with primary endpoints focusing on toxicity and three-month survival. Previous trials indicated promising results for MB-101 in treating this challenging cancer type. Mustang's leadership sees this as a significant milestone and aims to advance this potential treatment for patients dealing with these serious conditions.

Mustang Bio, Inc. (NASDAQ: MBIO) reported Q1 2021 financial results, highlighting significant clinical advancements. The FDA lifted a CMC hold on the MB-107 IND for infants with XSCID, enabling patient dosing soon. The company announced progress on MB-106, a CAR T cell therapy, with FDA approval to conduct a Phase 1/2 trial for B-NHL and CLL. As of March 31, 2021, cash equivalents totaled $130.4 million, up from $98.8 million at year-end 2020. Despite increased R&D and G&A expenses, the net loss was $15 million, or $0.19 per share.

Mustang Bio (NASDAQ: MBIO) announced that updated interim data from the Phase 1/2 clinical trial of MB-106, a CD20-targeted CAR T therapy, will be presented at the European Hematology Association 2021 Virtual Congress. The trial, conducted in collaboration with Fred Hutch, reported an overall response rate of 92% among 12 patients, with a complete response rate of 58%. Cytokine release syndrome occurred in 25% of patients, with manageable symptoms. The findings highlight the therapy's favorable safety profile compared to existing treatments.

Mustang Bio (NASDAQ: MBIO) announced the FDA's acceptance of its IND application for MB-106, a CAR T therapy targeting CD20 in patients with relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia. The Phase 1/2 multicenter trial is set to begin recruiting patients in Q3 2021. Previous studies indicated a favorable safety profile for MB-106, with an 89% overall response rate. With NHL and CLL accounting for significant cancer cases in the U.S., Mustang aims to provide effective treatment options for these patients.